P2RY12 and COVID-19: In vitro evidence indicated that a P2Y12 inhibitors e.g. clopidogrel or prasugrel could enhance the effect of aspirin to inhibit platelet activation (198) including platelet activation induced by plasma from COVID-19 patients an activity attributed to P2Y12 inhibitors not only blocking ADP, but by also impairing IL-6-mediated platelet activation (199).